Frazier Life Sciences VIII, L.P. 4

Accession 0001209191-18-053535

CIK 0001724344other

Filed

Oct 1, 8:00 PM ET

Accepted

Oct 2, 9:38 PM ET

Size

22.4 KB

Accession

0001209191-18-053535

Form 4

Period: 2018-09-28

10% Owner

Transactions

Conversion
Series B Convertible Preferred Stock
2018-09-28−7,000,000→ 0 total
→ Common Stock (337,707 underlying)
Conversion
Series B-1 Tranche B Convertible Preferred Stock
2018-09-28−6,651,574→ 0 total
→ Common Stock (320,898 underlying)
Conversion
Common Stock
2018-09-28+337,707→ 337,707 total
Conversion
Common Stock
2018-09-28+251,487→ 589,194 total
Conversion
Common Stock
2018-09-28+320,898→ 974,066 total
Purchase
Common Stock
2018-09-28$15.00/sh+375,887$5,638,305→ 1,349,953 total
Conversion
Series B-1 Tranche A Convertible Preferred Stock
2018-09-28−5,212,833→ 0 total
→ Common Stock (251,487 underlying)

10% Owner

Transactions

Conversion
Series B-1 Tranche A Convertible Preferred Stock
2018-09-28−5,212,833→ 0 total
→ Common Stock (251,487 underlying)
Conversion
Common Stock
2018-09-28+251,487→ 589,194 total
Purchase
Common Stock
2018-09-28$15.00/sh+375,887$5,638,305→ 1,349,953 total
Conversion
Common Stock
2018-09-28+337,707→ 337,707 total
Conversion
Common Stock
2018-09-28+320,898→ 974,066 total
Conversion
Series B Convertible Preferred Stock
2018-09-28−7,000,000→ 0 total
→ Common Stock (337,707 underlying)
Conversion
Series B-1 Tranche B Convertible Preferred Stock
2018-09-28−6,651,574→ 0 total
→ Common Stock (320,898 underlying)

10% Owner

Transactions

Conversion
Common Stock
2018-09-28+337,707→ 337,707 total
Conversion
Common Stock
2018-09-28+320,898→ 974,066 total
Conversion
Common Stock
2018-09-28+251,487→ 589,194 total
Purchase
Common Stock
2018-09-28$15.00/sh+375,887$5,638,305→ 1,349,953 total
Conversion
Series B Convertible Preferred Stock
2018-09-28−7,000,000→ 0 total
→ Common Stock (337,707 underlying)
Conversion
Series B-1 Tranche A Convertible Preferred Stock
2018-09-28−5,212,833→ 0 total
→ Common Stock (251,487 underlying)
Conversion
Series B-1 Tranche B Convertible Preferred Stock
2018-09-28−6,651,574→ 0 total
→ Common Stock (320,898 underlying)

10% Owner

Transactions

Conversion
Common Stock
2018-09-28+337,707→ 337,707 total
Conversion
Common Stock
2018-09-28+320,898→ 974,066 total
Conversion
Series B Convertible Preferred Stock
2018-09-28−7,000,000→ 0 total
→ Common Stock (337,707 underlying)
Conversion
Series B-1 Tranche B Convertible Preferred Stock
2018-09-28−6,651,574→ 0 total
→ Common Stock (320,898 underlying)
Purchase
Common Stock
2018-09-28$15.00/sh+375,887$5,638,305→ 1,349,953 total
Conversion
Series B-1 Tranche A Convertible Preferred Stock
2018-09-28−5,212,833→ 0 total
→ Common Stock (251,487 underlying)
Conversion
Common Stock
2018-09-28+251,487→ 589,194 total

Footnotes (3)

[F1]Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
[F2]The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.
[F3]This number includes an aggregate of 63,974 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.

Documents

1 file

Entasis Therapeutics Holdings Inc.

CIK 0001724344

Entity typeother

IncorporatedDE